Is Helicobacter pylori a cause of atrial fibrillation?

Future Cardiology

Volumn 2, Issue 4, 2006, Pages 429-439

  Andrew, Peter ^a   Montenero, Annibale Sandro ^b  

^a aATLAS Medical Research Inc   (Canada)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Amoxicillin; Arrhythmia; Atrial fibrillation; C reactive protein; Helicobacter pylori; Infection; Inflammation

Indexed keywords

ANTIARRHYTHMIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ARTIFICIAL HEART PACEMAKER; BACTERIAL COLONIZATION; CARDIOVERSION; CHRONIC DISEASE; CLINICAL FEATURE; DEFIBRILLATION; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART CATHETERIZATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; LABORATORY TEST; PATHOGENESIS; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PEPTIC ULCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; SINUS RHYTHM; STOMACH MUCOSA; THROMBOEMBOLISM;

EID: 33747729412     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.4.429     Document Type: Review

References (93)

1. Veenhuyzen GD, Simpson CS, Abdollah H: Atrial fibrillation. CMAJ 171(7), 755-760 (2004).
2. Fong IW: Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ 163(1), 49-56 (2000).
3. Larsen MM, Moern B, Fuller A, Andersen PL, Ostergaard LJ: Chlamydia pneumoniae and cardiovascular disease. Med. J. Aust. 177(10), 558-562 (2002).
4. Pellicano R, Oliaro E, Gandolfo N et al.: Ischemic cardiovascular disease and Helicobacter pylori. Where is the link? J. Cardiovasc. Surg. (Torino) 41(6), 829-833 (2000).
5. Rho RW, Page RL: Asymptomatic atrial fibrillation. Prog. Cardiovasc. Dis. 48(2), 79-87 (2005).
6. Fuster V, Ryden LE, Asinger RW et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J. Am. Coll. Cardiol. 38(4), 1231-1266 (2001).
7. Stewart S: Epidemiology and economic impact of atrial fibrillation. J. Cardiovasc. Nurs. 19(2), 94-102 (2004).
8. Abusaada K, Sharma SB, Jaladi R, Ezekowitz MD: Epidemiology and management of new-onset atrial fibrillation. Am. J. Manag. Care 10(Suppl. 3), S50-S57 (2004).
9. Hart RG, Halperin JL: Atrial fibrillation and stroke: concepts and controversies. Stroke 32(3), 803-808 (2001).
10. Stoddard MF: Risk of thromboembolism in acute atrial fibrillation or atrial flutter. Echocardiograpby 17(4), 393-405 (2000).
11. Hart RG, Halperin JL, Pearce LA et al.: Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann. Intern. Med. 138(10), 831-838 (2003).
12. Palmer AJ, Valentine WJ, Roze S, Lammert M, Spiesser J, Gabriel S: Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries. Curr. Med. Res. Opin. 21(1), 19-26 (2005).
13. Pelletier E, Hernandez J, Clark M, Justason BFM: Medicare costs and resource use associated with atrial fibrillation patients. Heart Rhythm 1, S57 (Abstract 175) (2004).
14. Evers SM, Struijs JN, Ament AJ, van Genugten ML, Jager JH, van den Bos GA: International comparison of stroke cost studies. Stroke 35(5), 1209-1215 (2004).
15. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92(7), 1954-1968 (1995).
16. Goette A, Honeycutt C, Langberg JJ: Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation 94(11), 2968-2974 (1996).
17. Poret P, Mabo P, Deplace C et al.: Is isolated atrial fibrillation genetically determined? Apropos of a familial history. Arch. Mal. Coeur Vaiss. 89(9), 1197-1203 (1996).
18. Brugada R: Is atrial fibrillation a genetic disease? J. Cardiovasc. Electrophysiol. 16(5), 553-556 (2005).
19. Wiesfeld AC, Hemels ME, van Tintelen JP, van den Berg MP, Van Veldhuisen DJ, Van Gelder IC: Genetic aspects of atrial fibrillation. Cardiovasc. Res. 67(3), 414-418 (2005).
20. Haissaguerre M, Jais P, Shah DC et al.: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 339(10), 659-666 (1998).
21. Khan R: Identifying and understanding the role of pulmonary vein activity in atrial fibrillation. Cardiovasc. Res. 64(3), 387-394 (2004).
22. van der Hooft CS, Heeringa J, van Herpen G, Kors JA, Kingma JH, Stricker BH: Drug-induced atrial fibrillation. J. Am. Coll. Cardiol. 44(11), 2117-2124 (2004).
23. Mihm MJ, Yu F, Carnes CA et al.: Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104(2), 174-180 (2001).
24. Olshansky B: Interrelationships between the autonomic nervous system and atrial fibrillation. Prog. Cardiovasc. Dis. 48(1), 57-78 (2005).
25. Costantini M, Crema A: The electrocardiology of atrial fibrillation. Ital. Heart J. 1(Suppl. 5), 632-640 (2000).
26. Schoonderwoerd BA, Van Gelder IC, Van Veldhuisen DJ, Van den Berg MP, Crijns HJ: Electrical and structural remodeling. role in the genesis and maintenance of atrial fibrillation. Prog. Cardiovasc. Dis. 48(3), 153-168 (2005).
27. Everett TH, Olgin JE: Basic mechanisms of atrial fibrillation. Cardiol. Clin. 22(1), 9-20 (2004).
28. Oral H: Mechanisms of atrial fibrillation: lessons from studies in patients. Prog. Cardiovasc. Dis. 48(1), 29-40 (2005).
29. Kopecky SL, Gersh BJ, McGoon MD et al.: The natural history of lone atrial fibrillation. A population-based study over three decades. N. Engl. J. Med. 317(11), 669-674 (1987).
30. Goldstein RN, Stambler BS: New antiarrhythmic drug for prevention of atrial fibrillation. Prog. Cardiovasc. Dis. 48(3), 193-208 (2005).
31. Levy S: Pharmacologic management of atrial fibrillation: current therapeutic strategies. Am. Heart J. 141(Suppl. 2), S15-S21 (2001).
32. Marine JE, Dong J, Calkins H: Catheter ablation therapy for atrial fibrillation. Prog. Cardiovasc. Dis. 48(3), 178-192 (2005).
33. Gillinov AM, Wolf RK: Surgical ablation of atrial fibrillation. Prog. Cardiovasc. Dis. 48(3), 169-177 (2005).
34. Aizawa Y: Catheter ablation of atrial fibrillation: its indication and problems. Intern. Med. 43(2), 164-166 (2004).
35. Nitta T: Surgery for atrial fibrillation. Ann. Thorac. Cardiovasc. Surg. 11(3), 154-158 (2005).
36. Earley MJ, Schilling RJ: Catheter and surgical ablation of atrial fibrillation. Heart 92(2), 266-274 (2006).
37. Lee J: Atrial fibrillation: the nonpharmacologic strategy. Mt. Sinai J. Med. 69(4), 232-241 (2002).
38. Joglar JA, Kowal RC: Electrical cardioversion of atrial fibrillation. Cardiol. Clin. 22(1), 101-111 (2004).
39. Dahlin J, Svendsen P, Gadsboll N: Poor maintenance of sinus rhythm after electrical cardioversion of patients with atrial fibrillation or flutter: a 5-year follow-up of 268 consecutive patients. Scand Cardiovasc. J. 37(6), 324-328 (2003).
40. Dayer M, Hardman SM: Special problems with antiarrhythmic drug in the elderly: safety, tolerability, and efficacy. Am. J. Geriatr. Cardiol. 11(6, 370-375 (2002).
41. Misaki T, Fukahara K: Recent topics on the surgical treatment for atrial fibrillation. Ann. Thorac. Cardiovasc. Surg. 10(5), 277-280 (2004).
42. Korantzopoulos P, Kolettis TM, Goudevenos JA, Siogas K: Errors and pitfalls in the non-invasive management of atrial fibrillation. Int. J. Cardiol. 104(2), 125-130 (2005).
43. Tsao HM, Chen SA: Evaluation of pulmonary vein stenosis after catheter ablation of atrial fibrillation. Card. Electrophysiol. Rev. 6(4), 397-400 (2002).
44. Pappone C: Pulmonary vein stenosis after catheter ablation for atrial fibrillation. J. Cardiovasc. Electrophysiol. 14(2), 165-167 (2003).
45. Humphries KH, Kerr CR, Steinbuch M, Dorian P: Limitations to antiarrhythmic drug use in patients with atrial fibrillation. CMAJ 171(7), 741-745 (2004).
46. Wu EQ, Birnbaum HG, Mareva M et al.: Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr. Med. Res. Opin. 21(10), 1693-1699 (2005).
47. Marshall DA, Levy AR, Vidaillet H et al.: Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann. Intern. Med. 141(9), 653-661 (2004).
48. Zhou L, Keane D, Reed G, Ruskin J: Thromboembolic complications of cardiac radiofrequency catheter ablation: a review of the reported incidence, pathogenesis and current research directions. J. Cardiovasc. Electrophysiol 10(4), 611-620 (1999).
49. Gonzalez MD: Rate control vs. pulmonary vein isolation. Am. J. Geriatr. Cardiol. 14(1), 26-30 (2005).
50. Teng MP, Catherwood LE, Melby DP: Cost effectiveness of therapies for atrial fibrillation. A review. Pharmacoeconomics 18(4), 317-333 (2000).
51. Weerasooriya R, Jais P, Le Heuzey JY et al.: Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin. Electrophysiol 26(1 Pt 2), 292-294 (2003).
52. Leonardi M, Bissett J: Prevention of atrial fibrillation. Curr. Opin. Cardiol. 20(5), 417-423 (2005).
53. Montenero AS, Mollichelli N, Zumbo F et al.: Helicobacter pylori and atrial fibrillation: a possible pathogenic link. Heart 91(7), 960-961 (2005).
54. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A: Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96(4), 1180-1184 (1997).
55. Chung MK, Martin DO, Sprecher D et al.: C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104(24), 2886-2891 (2001).
56. Dernellis J, Panaretou M: C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta. Cardiol. 56(6), 375-380 (2001).
57. Gaudino M, Andreotti F, Zamparelli R et al.: The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 108(Suppl. 1), 195-199 (2003).
58. Aviles RJ, Martin DO, Apperson-Hansen C et al.: Inflammation as a risk factor for atrial fibrillation. Circulation 108(24), 3006-3010 (2003).
59. Sata N, Hamada N, Horinouchi T et al.: C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J. 45(3), 441-445 (2004).
60. Anderson JL, Allen Maycock CA, Lappe DL et al.: Frequency of elevation of C-reactive protein in atrial fibrillation. Am. J. Cardiol. 94(10), 1255-1259 (2004).
61. Watanabe T, Takeishi Y, Hirono O et al.: C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart Vessels 20(2), 45-49 (2005).
62. Wazni O, Martin DO, Marrouche NF et al.: C-reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 91 (10), 1303-1305 (2005).
63. Hatzinikolaou-Kotsakou E, Tziakas D, Hotidis A et al.: Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. Am. J. Cardiol. 97(5), 659-661 (2006).
64. Seguin P, Laviolle B, Maurice A, Leclercq C, Malledant Y: Atrial fibrillation in trauma patients requiring intensive care. Intensive Care Med. 32(3), 398-404 (2006).
65. Lamm G, Auer J, Weber T, Berent R, Ng C, Eber B: Postoperative white blood cell count predicts atrial fibrillation after cardiac surgery. J. Cardiothorac. Vasc. Anesth. 20(1), 51-56 (2006).
66. Delaney B, Moayyedi P, Forman D: Helicobacter pylori infection. Clin. Evid. 13, 518-534 (2005).
67. Suerbaum S, Michetti P: Helicobacter pylori infection. N. Engl. J. Med. 347(15), 1175-1186 (2002).
68. Goh KL: Helicobacter pylori and peptic ulcer disease: a causal link. Med. J. Malaysia 52(2), 161-168 (1997).
69. Figueiredo C, Machado JC, Yamaoka Y: Pathogenesis of Helicobacter pylori infection. Helicobacter 10(Suppl. 1), S14-S20 (2005)
70. Kikuchi S, Dore MP: Epidemiology of Helicobacter pylori infection. Helicobacter 10(Suppl. 1), S1-S4 (2005).
71. Parsonnet J, Shmuely H, Haggerty T: Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 282(23), 2240-2245 (1999).
72. Logan RP, Walker MM: ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. Br. Med. J. 323(7318), 920-922 (2001).
73. Granstrom M, Tindberg Y, Blennow M: Seroepidemiology of Helicobacter pylori infection in a cohort of children monitored from 6 months to 11 years of age. J. Clin. Microbiol. 35(2), 468-470 (1997).
74. Aro P, Storskrubb T, Ronkainen J et al.: Peptic ulcer disease in a general adult population: the kalixanda study: a random population-based study. Am. J. Epidemiol. 163(11), 1025-1034 (2006).
75. Matysiak-Budnik T, Megraud F: Epidemiology of Helicobacter pylori infection with special reference to professional risk. J. Physiol. Pharmacol. 48(Suppl. 4), 3-17 (1997).
76. Feldman RA: Confounding factors in observational and intervention studies. Ital. J. Gastroenterol. Hepatol. 30(Suppl. 3), S248-S253 (1998).
77. Brown LM: Helicobacter pylori: epidemiology and routes of transmission. Epidemiol. Rev. 22(2), 283-297 (2000).
78. Franceschi F, Leo D, Fini L et al.: Helicobacter pylori infection and ischaemic heart disease: an overview of the general literature. Dig. Liver Dis. 37(5), 301-308 (2005).
79. Mendall MA, Goggin PM, Molineaux N et al.: Relation of Helicobacter pylori infection and coronary heart disease. Br. Heart J. 71(5), 437-439 (1994).
80. Pasceri V, Cammarota G, Patti G et al.: Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 97(17), 1675-1679 (1998).
81. Bergman MP, Vandenbroucke-Grauls CM, Appelmelk BJ et al.: The story so far: Helicobacter pylori and gastric autoimmunity. Int. Rev. Immunol. 24(1-2), 63-91 (2005).
82. Negrini R, Savio A, Appelmelk BJ: Autoantibodies to gastric mucosa in Helicobacter pylori infection. Helicobacter 2(Suppl. 1), S13-S16 (1997).
83. +-ATPase in the rat heart. Acta. Physiol. Scand. 179(3), 251-262 (2003).
84. + pump*. Clin. Sci. (Lond). 95(1), 3-17 (1998).
85. McDonough AA, Velotta JB, Schwinger RH, Philipson KD, Farley RA: The cardiac sodium pump: structure and function. Basic Res. Cardiol. 97(Suppl. 1), 19-24 (2002).
86. Candelli M, Nista EC, Carloni E et al.: Treatment of H. pylori infection: a review. Curr. Med. Chem. 12(4), 375-384 (2005).
87. Aebischer T, Schmitt A, Walduck AK, Meyer TF: Helicobacter pylori vaccine development: facing the challenge. Int. J. Med. Microbiol. 295(5), 343-353 (2005).
88. Gooderham MJ, Bolli P, Fernandez PG: Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. Ann. Pharmacother. 33(7-8), 796-799 (1999).
89. Sarabanda AV, Bunch TJ, Johnson SB et al.: Efficacy and safety of circumferential pulmonary vein isolation using a novel cryothermal balloon ablation system. J. Am. Coll. Cardiol. 46(10), 1902-1912 (2005).
90. Kuo CT, Luqman N, Lin KH, Lee YS: Atrial fibrillation: new horizons. Chang Gung Med. J. 26(10), 712-721 (2003).
91. Di Biase M, Troccoli R, Brunetti ND: Non-antiarrhythmic drugs for the prevention of cardiac arrhythmias. Ital. Heart J. 6(3), 175-179 (2005).
92. Harris WS: Extending the cardiovascular benefits of omega-3 fatty acids. Curr. Atheroscler. Rep. 7(5), 375-380 (2005).
93. Mazgalev TN: Drugs, ablation, denervation... and now fish oil: the global war on AF. J. Cardiovasc. Electrophysiol. 16(11), 1195-1199 (2005).